Presymptom Health’s core product, InfectiClear, is an AI-driven diagnostic that analyses host RNA responses to detect infection—potentially up to three days earlier than pathogen-based methods. The test was trained and validated on 15 years of patient data and recent clinical trial results indicate it may have more than 95% accuracy at ruling out lower respiratory tract infection. The technology provides an early, highly sensitive signal for infection or sepsis, aiming to reduce delays and inaccuracies associated with traditional tests and help curb unnecessary antibiotic use. The company is making InfectiClear broadly compatible with multiple PCR platforms to ease NHS adoption, including point-of-care and lab workflows. Current funding announced is non-dilutive grant funding to accelerate platform compatibility and shorten test times to roughly 40–60 minutes. A six-month feasibility project with Health Innovation Oxford and Thames Valley will assess barriers to NHS adoption and the best rollout approach. Presymptom Health develops AI and machine-learning tools to identify infection and sepsis earlier than existing diagnostics, claiming detection up to three days before formal clinical diagnosis. The company analyses samples from a large biobank to extract signals that enable substantially faster detection of infections and sepsis. CEO Dr Iain Miller has emphasized that sepsis diagnostics have not advanced in more than a century and are often only possible once advanced symptoms and organ failure appear. The startup cites that each hour sepsis goes untreated raises mortality by about 10%, and notes nearly 48,000 sepsis deaths annually in Britain. Financially, Presymptom Health has secured external backing, including a recent raise reported in the article. The technology is positioned as an AI-driven improvement to clinical workflows for earlier intervention.

Total raised

$2M

Funding rounds

2

Latest round

Grant

Latest activity

Feb 2025